Crinetics (CRNX) Q2 Revenue Jumps 150%
Crinetics Pharmaceuticals (NASDAQ:CRNX), a biotechnology company focused on developing oral therapies for rare endocrine diseases, reported its latest quarterly results on August 7, 2025, for the second quarter of fiscal 2025. The most critical news was that GAAP revenue rose to $1.0 million, surpassing the consensus GAAP estimate of $0.61 million. However, the company's GAAP net loss per share widened to $(1.23), a larger loss than the anticipated $(1.08) per share, driven by higher research and development and administrative spending. The period saw rapid scaling ahead of the potential commercial debut for its lead drug, paltusotine, with a noticeably larger GAAP net loss of $115.6 million compared to $74.1 million in Q2 2024. Overall, the quarter reflected solid execution on clinical and commercial preparations but underscored the ongoing pre-commercial stage and heavy investment cycle.
Source: Analyst estimates for the quarter provided by FactSet.
The company specializes in discovering and developing oral, small-molecule drugs for endocrine diseases where existing treatments are often injectable and less convenient. Its lead programs target rare conditions such as acromegaly, carcinoid syndrome, congenital adrenal hyperplasia (CAH), and Cushing’s disease. The central products in development are paltusotine, an oral therapy for acromegaly and carcinoid syndrome, and atumelnant, aimed at CAH and Cushing’s disease. Both are in late-stage clinical or regulatory review, with additional drug candidates advancing in earlier stages.
Source Fool.com
